Baird analyst Colleen Kusy lowered the firm’s price target on Apellis (APLS) to $47 from $55 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results and the bigger than expected Syfore miss. However, its market share gain is encouraging.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target lowered to $26 from $30 at Wells Fargo
- Optimistic Growth Potential for Apellis Pharmaceuticals Despite Temporary Setbacks
- Hold Rating on Apellis Pharmaceuticals Amid Revenue Uncertainty and Competitive Pressures
- Apellis Pharmaceuticals Reports Q1 2025 Financial Results
- Apellis Pharmaceuticals’ Earnings Call Highlights Achievements and Challenges